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Thuya occidentalis is used in popular medicine in the treatment of condyloma
and has antibacterial action. Red blood cells (RBC) labeled with technetium-
99m (99mTc) are used for several evaluations in nuclear medicine. This label-
ing depends on a reducing agent, usually stannous ion. Any drug which alters
the labeling of the tracer could be expected to modify the disposition of the
radiopharmaceutical. We have evaluated the influence of T occidentalis extract
on the labeling ofRBC and plasma proteins with 99mTc. Blood was withdrawn
and incubated with T occidentalis (0.25; 2.5; 20.5; and 34.1 percent v/v).
Stannous chloride (1.2 pg/ml) was added and then 99mTc was added. Plasma
(P) and blood cells (BC) were isolated, also precipitated with trichloroacetic
acid and soluble (SF) and insoluble fractions (IF) separated. The analysis ofthe
results shows that there is a decrease in radioactivity (from 97.64 to 75.89 per-
cent) in BC with 34.1 percent of the drug. In the labeling process ofRBC with
99mTc, the stannous and pertechnetate ions pass through the membrane, so we
suggest that the T occidentalis effect can be explained (i) by an inhibition ofthe
transport of these ions, (ii) by damage in membrane, (iii) by competition with
the cited ions for the same binding sites, or (iv) by possible generation of reac-
tive oxygen species that could oxidize the stannous ion.
INTRODUCTION
Thuya occidentalis (American arbor vitae) extract is used in popular medicine as
expectorant, diuretic, antihelmintic, stimulant, and in rheumatism treatment. It acts on the
renal epithelium and has a toxic action in bladder muscles. It is used in the treatment of
cystitis and prostatic hypertrophy in senile men and in urinary incontinence in women. As
a tincture, it is popularly used as an abortifacient, as an agent for cauterization ofpapillo-
mas and condylomatous warts [1, 2, 3]. The biological effects ofT occidentalis have been
studied previously [1, 2, 3, 4].
Technetium-99m (99mTc) has been the most utilized radionuclide in clinical nuclear
medicine procedures [5, 6, 7], and it has also been used in basic research [8, 9, 10, 11, 12].
Its wide use in nuclear medicine is due to its optimal physical characteristics (half-life of
6h, gamma ray energy of 140 keV and resulting minimal dose to the patient), convenient
availability from a 99Mo/99mTc generator, and negligible environmental impact. Almost
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all scanning devices currently in use are optimized fordetecting the readioactive emission
from this radionuclide [5, 6].
Ofthe many applications of99mTc-labeled red blood cells (RBC)e most important is
in cardiovascular nuclear medicine, where one tries to image the heart to determine its
functional status as a pump, to calculate the left ventricular function by measuring the
ejection fractions, and to evaluate wall motion abnormalities. Some otherapplications are
in the detection ofgastrointestinal bleeding and in the determination of the RBC mass in
patients [5, 6, 13]. If one damages the RBC, one can do selective spleen imaging (since
damaged cells are rapidly sequestered by the spleen) [14]. RBC have been labeled with
99mTc for in vitro [6, 14], in vivo [5, 6, 13] or in vivo/in vitro [5, 6, 15] techniques. The
labeling process with 99mTc depends on areducing agent and stannous ion (Sn) is usual-
ly used for this purpose. When whole blood is employed in the labeling of RBC with
99mTc, radioactivity is found in blood cells, however it is also bound to plasma proteins.
This labeling process depends on optimal stannous chloride concentration [16, 17, 18, 19,
20]. Stannous and pertechnetate ions cross the RBC membrane, probably by active trans-
port [21]. The radionuclide is mainly bound to the hemoglobin molecule [22, 23, 24].
Several of the cellular labeling steps have been well-characterized. The band-3 anion
transport system [17] and calcium channels [16] may be the ways that 99mTc [17] and Sn
[16], respectively, reach the interior of the RBC.
Unexpected patterns of radiopharmaceutical biodistribution can be associated with a
disease. However many factors, including drug therapy, radiation therapy, dietary condi-
tions, besides pathological process could affect the biodistibution ofthe radiopharmaceu-
tical. Any chemical, physical or biological agent which alters (i) the chemical identity of
the tracer, (ii) the physiological status of the organ ofinterest, or (iii) its binding capabil-
ity to plasma proteins or other blood element, could be expected to modify the radiophar-
macokinetics and the disposition of the radiopharmaceutical in the specific target. If
unknown, such factors may lead to poor visualization, requiring the repetition of the
examination procedure resulting in unnecessary irradiation to the patient or even misdi-
agnosis. Many drugs have been reported to affect the biodistribution of different radio-
pharmaceuticals [5, 25, 26]. The labeling of red blood cells with 99mTc has been influ-
enced by patient medications [5, 25] or the labeling conditions [15, 20, 27, 28]. Therapy
with ,B-adrenergic blockers, calcium channel blockers ornitrate may result in normal exer-
cise radionuclide ventriculograms even in the presence of significant coronary artery dis-
ease. Thus, the presence of the disease may be missed and/or underestimated [25].
In this way, an unusual behavior of the radiopharmaceutical could, on occasion, be
due to adrug. Nevertheless, there is not awell established in vitro model to study the inter-
action oftherapeutic drugs with radiopharmaceuticals. Thus, we have evaluated the influ-
ence of a T occidentalis extract on the labeling ofRBC and plasmaproteins with Tc-99m
using an in vitro technique.
MATERIAL AND METHODS
These experiments were performed without sacrificing the animals. Heparinized
whole blood was withdrawn from Wistar rats. Samples of0.5 ml were incubated with 100
,ul ofdifferentconcentrations ofacommercial (Laboratorio Simoes LTDA, Rio de Janeiro,
Brazil) T occidentalis extract (0.25; 2.5; 20.5; and 34.1 percent v/v) for 1 hr at room tem-
perature. A sample ofheparinized whole blood was incubated with saline solution (NaCI,
0.9 percent) as control. Then, 0.5 ml of stannous chloride (1.2 ,ug/ml), as SnCl2.2H20
(Merck, Brazil) was added and the incubation continued for another 1 hr. After this peri-
od oftime, 99mTc (0.1 ml), as sodium pertechnetate, recently eluted from a99Mo/99mTc
generator (Instituto de Pesquisas Energeticas e Nucleares, Comissao Nacional de Energia
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Nuclear, Brazil), was added and the incubation continued for another 10 min. These sam-
ples were centrifuged and plasma (P) and blood cells (BC) were separated. Samples (20
1) ofP and BC were precipitated with 1 ml oftrichloroacetic acid (TCA) (5 percent) and
soluble (SF) and insoluble fractions (IF) were separated. The radioactivity in P, BC, IF-P,
SF-P, IF-BC and SF-BC were determined in awell counter (Clinigamma, gammacounter,
LKB, Wallac, Finland). After that, the percent of radioactivity (percent rad) was calcu-
lated, as previously described [19, 20]. A statistical analysis (ANOVA test) was employed
to compare the experimental data.
RESULTS
Table 1 shows the distribution of the radioactivity in plasma and blood cells from
whole blood treated with different concentrations of T occidentalis extract. The analysis
ofthe results indicates that there is a significant decrease (p < .05) in the uptake of99mTc
by the red blood cells (from 97.64 to 75.89 percent) with the concentration of 34.1 per-
cent (v/v) ofthe extract.
Table 2 shows the fixation of the radioactivity in the insoluble fraction of plasma
obtained from whole blood treated with different concentrations of T. occidentalis
extract. The analysis of the results indicates that there is a significant decrease (p < .05)
Table 1. Effect of Thuya occidentallis on the labeling ofblood cells and plasma with 99mTc.
Thuya occidentallis Blood cells (BC) Plasma (P)
concentrations (v/v)
0.00 (control) 97.64 ± 1.43 2.24 ± 1.43
0.25 95.40 ± 4.38 4.60 ± 4.38
2.52 92.63 ± 5.91 7.27 ± 5.91
20.50 90.88 ± 4.61 9.12 ± 4.61
34.10 75.89±6.29 24.11 ±6.29
Samples ofheparinized blood were incubated with differentconcentrations ofT. occidentalis extract
(0.25; 2.5; 20.5; and 34.1 percent v/v). A sample of heparinized whole blood was incubated with
saline solution (NaCl, 0.9 percent) as control. Then, stannous chloride (1.2 pg/ml) and 99mTc, as
sodium pertechnetate were added. The radioactivity in P and BC was determined in a well counter
and the percent ofradioactivity (percent rad) was calculated. A statistical analysis (ANOVA test, n
= 12) was employed to compare the results
in the fixation of 99mTc in plasma proteins when the concentrations of 20.50 and 34.1
percent (v/v) of the referred drug are employed.
Table 3 shows the fixation ofthe radioactivity in the insoluble fraction of blood cells
obtained from whole blood treated with different concentrations ofT occidentalis extract.
The analysis of the results indicates that there is not a significant decrease in the fixation
of 99mTc in insoluble fractions of the blood cells at any of the tested concentrations of
the drug.
DISCUSSION
Contrary to the numerous theoretical and practical studies ofthe conventionally used
pharmacologically active agents, the data concerning interaction of diagnostic agents,
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Table 2. Effect of Thuya occidentallis on the labeling ofplasma proteins (PP) with 99mTc
Thuya occidentallis Insoluble fraction (IF-P) Soluble fraction (SF-P)
concentrations (v/v)
0.00 (control) 79.63 ± 3.71 20.27 ± 3.71
0.25 78.00 ± 5.67 22.00 ± 5.67
2.52 73.65 ± 4.78 26.35 ± 4.78
20.50 22.88 ± 5.56 77.12 + 5.56
34.10 46.91 ± 3.73 53.09 + 3.73
Samples ofheparinized blood were incubated with different concentrations ofT occidentalis extract
(0.25; 2.5; 20.5; and 34.1 percent v/v). A sample of heparinized whole blood was incubated with
saline solution (NaCl, 0.9 percent) as control. Then, stannous chloride (1.2 pg/ml) and 99mTc, as
sodium pertechnetate were added. These samples were centrifuged and plasma (P) and blood cells
(BC) were separated. Samples (20 p1) ofP were precipitated with trichloroacetic acid (TCA) 5 per-
cent and soluble (SF) and insoluble fractions (IF) were separated. The radioactivity in SF-P and IF-
P was determined in a well counter and the percent ofradioactivity (percent rad) was calculated. A
statistical analysis (ANOVA test, n = 12) was employed to compare the results
Table 3. Effect of Thuya occidentallis on the labeling of blood cells proteins with 99mTc
Thuya occidentallis Insoluble fraction (IF-BC) Soluble fraction (SF-BC)
concentrations (v/v)
0.00 (control) 79.70 ± 2.12 20.30 ± 2.12
0.25 80.43 ± 2.39 19.57 ± 2.39
2.52 79.59 ± 2.62 20.41 ± 2.62
20.50 79.27 ± 2.51 20.63 ± 2.51
34.10 76.19 ± 3.14 23.81 ± 3.14
Samples ofheparinized blood were incubated with different concentrations ofT occidentalis extract
(0.25; 2.5; 20.5; and 34.1 percent v/v). A sample of heparinized whole blood was incubated with
saline solution (NaCl, 0.9 percent) as control. Then, stannous chloride (1.2 pg/ml) and 99mTc, as
sodium pertechnetate were added. These samples were centrifuged and plasma (P) and blood cells
(BC) were separated. Samples (20 p1) of BC were precipitated with trichloroacetic acid (TCA) S
percent and soluble (SF) and insoluble fractions (IF) were separated. The radioactivity in SF-BC and
IF-BC was determined in a well counter and the percent of radioactivity (percent rad) was calcu-
lated. A statistical analysis (ANOVA test, n = 12) was employed to compare the results.
including radiopharmaceuticals, are relatively scarce. A therapeutic drug can also modify
the nature/amount of the 99mTc-radiopharmaceutical bound to blood elements and this
may result in unexpected behavior of the radiopharmaceutical. There is not a well-estab-
lished model to study the interaction oftherapeutic drugs with radiopharmaceuticals. Care
must be taken when attempting to extrapolate experimental data to the clinical situation,
since the observed effects may depend on the amounts of the drug [5, 25, 26].
We agree with Hesslewood and Leung [25] that many reports on drug interactions
with radiopharmaceuticals are anecdotal and in some instances a direct cause and effect
relationship has not been unequivocally established. This situation could be remedied with
the development of in vitro tests to evaluate the drug/radiopharmaceutical interactions.
We have studied the effect of a commercial extract of T occidentalis on the labeling
of red blood cells with 99mTc and the fixation of this radionuclide to insoluble fractions
of plasma (plasma proteins) and to blood cells (blood cells proteins). In the labeling
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process of RBC with Tc-99m, the stannous and pertechnetate ions pass through the plas-
ma membrane. Although the exact mechanism of the effect of T occidentalis (34.10 per-
cent v/v) on the labeling of red blood cells is not elucidated, we suggest that it might be
explained (i) by a direct inhibition (chelating action) of the referred ions, (ii) by damage
induced in the plasma membrane, or (iii) by competition of the cited ions for the same
binding sites.
Plasma proteins (PP) were also labeled with the referred radionuclide. 99mTc-labeled
PP have been used to locate the placenta, to evaluate cardiac function and pulmonary per-
fusion, to determine blood volume, and to study gastrointestinal protein loss [5, 6]. When
a concentration of T occidentalis extract (20.50 and 34.10 percent v/v) is incubated with
whole blood there is a decrease in the fixation of99mTc in the insoluble fraction ofplas-
ma (plasma proteins). The chemical agents present in this extract could (i) bind (chelating
action) to stannous and pertechnetate ions and/or (ii) bind to the binding sites of 99mTc
in plasma proteins.
Red blood cell proteins can be labeled with 99mTc, mainly in the J-chain of the
hemoglobin molecule [22, 23]. The fixation ofthis radioactivity seems not to be modified
by T occidentalis extract. Another possibility is that there is a blocking of the labeling
inside the cells, but the 99mTc (free) could be precipitated with the red blood cell ghost.
The genotoxic effect of another natural product extract (Paullinia cupana) has been
associated to the generation of reactive oxygen species [29] that are oxidizing agents. If
T occidentalis would be capable of generating reactive oxygen species, these could oxi-
dize the stannous to stannic ion. This action could explain the decrease on the labeling of
red blood cells and plasma proteins with 99mTc in the presence ofhigh concentration of
T occidentalis extract.
We can conclude that, depending on T occidentalis concentration, the labeling ofred
blood cells with 99mTc can be decreased, as well as the fixation ofradioactivity in plas-
ma proteins, at least, when an in vitro technique to label red blood cells is employed.
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